WYBRANT SYSTEM PRODUCTS CORPORATION ET AL., PETITIONERS,

v.

FEDERAL TRADE COMMISSION, RESPONDENT

PER CURIAM.

Petitioner’s advertisements were placed in newspapers with interstate circulation; and though designed primarily to sell their hair and scalp treatments, the material clearly was “likely to induce * * * indirectly the purchase of” the preparations that they also sold in substantial quantities for home use.1 This is sufficient to establish the Commission’s jurisdiction under § 12(a)(1) of the Federal Trade Commission Act, 15 U.S.C. § 52(a) (1). Mueller v. United States, 5 Cir., 262 F. 2d 443. The firm testimony of the Commission’s several expert witnesses that petitioners’ preparations and treatments cannot cure male pattern baldness provides ample basis for the Trial Examiner’s conclusion that the advertisements were false. And since these witnesses freely conceded that some authorities had expressed somewhat contrary views, we do not think the Trial Examiner’s refusal to receive in evidence the medical treatises that petitioners offered constituted reversible error. See Dolcin Corp. v. F. T. C., 94 U.S.App.D.C. 247, 219 F. 2d 742, 747-749, certiorari denied 348 U.S. 981, 75 S.Ct. 571, 99 L.Ed. 763.

Affirmed.

. Neither the Commission nor the Trial Examiner determined whether the use of preparations in connection with an office treatment constitutes a sale under § 12 of the Federal Trade Commission Act, 15 U.S.C. § 52. We construe the Commission’s order — directed at advertisements by petitioners “in connection with the offering for sale, sale or distribution” of their preparations — to be similarly limited.